Spain· ES:106346002
TYSABRI 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
A medicinal product containing natalizumab, registered in Spain by Biogen Netherlands B.V..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- natalizumab
- Manufacturer
- Biogen Netherlands B.V.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Natalizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTYSABRIBiogen Netherlands B.V., Badhoevedorp
- United KingdomTysabri 150mg/1ml solution for injection pre-filled syringesBiogen Idec Ltd
- BelgiumTysabri 150 mgBiogen Netherlands
- NorwayTysabriBiogen Netherlands B.V.
- PolandTysabriBiogen Netherlands B.V.
- SwedenTysabri 150 mg Injektionsvätska, lösning i förfylld sprutaBiogen Netherlands B.V.
- IcelandTysabriBiogen Netherlands B.V.
- FinlandTyrukoAbacus Medicine A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tyruko, Tysabri
- Liechtenstein · Tyruko, Tysabri
- Norway · Tyruko, Tysabri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b95c7a5b-f291-403c-9cc5-250ff043aa75 GET /v1/drugs/b95c7a5b-f291-403c-9cc5-250ff043aa75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1619019688000}",
"nregistro": "106346002",
"substance": "natalizumab"
}See everything about natalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.